Evidence map›Paper›PMID 36045346›Full record

ArticleMolecular cancer2022

PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma.

I Garces de Los Fayos Alonso, L Zujo, I Wiest, P Kodajova, G Timelthaler, S Edtmayer, M Zrimšek, S Kollmann, C Giordano, M Kothmayer and 30 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. JAK-STAT Signaling in Autoimmunity and Cancer.ImmunoTargets and therapy · 2025
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors at 14 institutions in 6 countries.

I Garces de Los Fayos AlonsoDepartment of Pathology, Medical University of Vienna, 1090, Vienna, Austria.
L ZujoDepartment of Pathology, Medical University of Vienna, 1090, Vienna, Austria.
I WiestDepartment of Pathology, Medical University of Vienna, 1090, Vienna, Austria.
P KodajovaUnit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria.
G TimelthalerCenter for Cancer Research, Medical University of Vienna, 1090, Vienna, Austria.
S EdtmayerDivision Pharmacology, Department of Pharmacology, Physiology and Microbiology, Karl Landsteiner University of Health Sciences, 3500, Krems, Austria.
M ZrimšekDepartment of Pathology, Medical University of Vienna, 1090, Vienna, Austria.
S KollmannInstitute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria.
C GiordanoDepartment of Pathology, Medical University of Vienna, 1090, Vienna, Austria.
M KothmayerDepartment of Pathology, Medical University of Vienna, 1090, Vienna, Austria.
H A NeubauerInstitute of Animal Breeding and Genetics, Unit of Functional Cancer Genomics, University of Veterinary Medicine Vienna, 1210, Vienna, Austria.
S DeyDepartment of Dermatology, Medical University of Graz, 8036, Graz, Austria.
M SchledererDepartment of Pathology, Medical University of Vienna, 1090, Vienna, Austria.
B S SchmalzbauerUnit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria.
T LimbergerDepartment of Pathology, Medical University of Vienna, 1090, Vienna, Austria.
C ProbstDepartment of Pathology, Medical University of Vienna, 1090, Vienna, Austria.
O PuschCentre for Anatomy and Cell Biology, Medical University of Vienna, 1090, Vienna, Austria.
S HöglerUnit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria.
S TangermannUnit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria.
O MerkelDepartment of Pathology, Medical University of Vienna, 1090, Vienna, Austria.
A I SchieferDepartment of Pathology, Medical University of Vienna, 1090, Vienna, Austria.
C KornauthDepartment of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090, Vienna, Austria.
N PrutschDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
M ZimmermanDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
B AbrahamDepartment of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
J AnagnostopoulosInstitute of Pathology, University of Wuerzburg, 97080, Würzburg, Germany.
L Quintanilla-MartinezInstitute of Pathology and Neuropathology and Cluster of excellence iFIT, "Image-Guided and Functionally Instructed Tumor Therapy", University of Tübingen, 72076, Tübingen, Germany.
S MathasDepartment of Hematology, Oncology, and Cancer Immunology, Charité-Medical University of Berlin, 12200, Berlin, Germany.
P WolfDepartment of Dermatology, Medical University of Graz, 8036, Graz, Austria.
D StoiberDivision Pharmacology, Department of Pharmacology, Physiology and Microbiology, Karl Landsteiner University of Health Sciences, 3500, Krems, Austria.
P B StaberDepartment of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090, Vienna, Austria.
G EggerDepartment of Pathology, Medical University of Vienna, 1090, Vienna, Austria.
W KlapperDepartment of Pathology, Hematopathology Section and Lymph Node Registry, University of Kiel/University Hospital Schleswig-Holstein, 24105, Kiel, Germany.
W WoessmannPediatric Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
T A LookDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
P GunningDepartment of Chemical and Physical Sciences, University of Toronto Mississauga, Mississauga, ON, L5L 1C6, Canada.
S D TurnerDivision of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, CB20QQ, UK.
R MorigglInstitute of Animal Breeding and Genetics, Unit of Functional Cancer Genomics, University of Veterinary Medicine Vienna, 1210, Vienna, Austria.
S Lagger *Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, 1210, Vienna, Austria.
L Kenner *Department of Pathology, Medical University of Vienna, 1090, Vienna, Austria. Lukas.kenner@meduniwien.ac.at.
Medical University of Vienna · ATUniversity of Veterinary Medicine Vienna · ATHarvard University · USMedical University of Graz · ATComprehensive Cancer Center Vienna · ATKarl Landsteiner University of Health Sciences · ATKiel University · DEMax Delbrück Center · DESt. Jude Children's Research Hospital · USUniversität Hamburg · DEUniversity of Cambridge · GBUniversity of Toronto · CAUniversity of Tübingen · DEUniversity of Würzburg · DE

Funding

Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in CancerR35CA210064 · NCI · DANA-FARBER CANCER INST · PI LOOK, A. THOMAS · 2016 to 2022
$7.3M
Austrian Science Fund FWF I 4066Austrian Science Fund FWF I 4154Austrian Science Fund FWF I 4156Austrian Science Fund FWF P 27132NCI NIH HHS R35 CA210064
6 · The paper itself

Abstract

backgroundAnaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin T cell lymphoma commonly driven by NPM-ALK. AP-1 transcription factors, cJUN and JUNb, act as downstream effectors of NPM-ALK and transcriptionally regulate PDGFRβ. Blocking PDGFRβ kinase activity with imatinib effectively reduces tumor burden and prolongs survival, although the downstream molecular mechanisms remain elusive. METHODS AND

resultsIn a transgenic mouse model that mimics PDGFRβ-driven human ALCL in vivo, we identify PDGFRβ as a driver of aggressive tumor growth. Mechanistically, PDGFRβ induces the pro-survival factor Bcl-x

conclusionsWe therefore propose PDGFRβ as a novel biomarker and introduce PDGFRβ-STAT3/5 signaling as an important axis in aggressive ALCL. Furthermore, we suggest that inhibition of PDGFRβ or STAT3/5 improve existing therapies for both previously untreated and relapsed/refractory ALK

Indexed as

Lymphoma, Large-Cell, AnaplasticReceptor, Platelet-Derived Growth Factor betaSTAT3 Transcription FactorSTAT5 Transcription FactorAnaplastic Lymphoma KinaseAnimalsCarcinogenesisCell Line, TumorHumansMicePhosphorylationSignal TransductionAnaplastic Lymphoma KinaseReceptor, Platelet-Derived Growth Factor betaSTAT3 protein, humanSTAT3 Transcription FactorSTAT5 Transcription FactorALCLApoptosisNPM-ALKPDGFRβSTAT3STAT5ASTAT5B

Identifiers

PMID36045346
PMCPMC9434917
OpenAlexW4293755562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.